<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27436084</article-id>
<article-id pub-id-type="pmc">5536332</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2016.04.023</article-id>
<article-id pub-id-type="manuscript">NIHMS885312</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ade</surname>
<given-names>Kristen K.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Yehong</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hamann</surname>
<given-names>Harold C.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Hare</surname>
<given-names>Justin K.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Weirui</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quian</surname>
<given-names>Anna</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Sunil</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhagat</surname>
<given-names>Srishti</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguiz</surname>
<given-names>Ramona M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wetsel</surname>
<given-names>William C.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conn</surname>
<given-names>P. Jeffrey</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dzirasa</surname>
<given-names>Kafui</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huber</surname>
<given-names>Kimberly M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Calakos</surname>
<given-names>Nicole</given-names>
</name>
</contrib>
<aff id="A1">Departments of Neurology (KKA, YW, HCH, JKO’H, AQ, SB, NC), Neurobiology (KKA, YW, HCH, JKO’H, SB, NC), and Psychiatry and Behavioral Sciences (SK, RMR, WCW, KD), Duke University Medical Center, Durham, North Carolina; Department of Neuroscience (WG, KMH), University of Texas Southwestern Medical Center, Dallas, Texas; and Department of Pharmacology (PJC), Vanderbilt University Medical Center, Nashville, Tennessee.</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Address correspondence to Nicole Calakos, M.D., Ph.D., Duke University Medical Center, Neurobiology and Neurology, Box 2900, BRB Rm 201E - Neurology, Durham, NC, 27710; <email>nicole.calakos@duke.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P39">
<bold>DISCLOSURES</bold>
</p>
<p id="P40">All authors report no biomedical financial interests or potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>80</volume>
<issue>7</issue>
<fpage>522</fpage>
<lpage>533</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2016.04.023-->
<abstract>
<sec id="S1">
<title>BACKGROUND</title>
<p id="P1">Development of treatments for obsessive-compulsive disorder (OCD) is hampered by a lack of mechanistic understanding about this prevalent neuropsychiatric condition. Although circuit changes such as elevated frontostriatal activity are linked to OCD, the underlying molecular signaling that drives OCD-related behaviors remains largely unknown. Here, we examine the significance of type 5 metabotropic glutamate receptors (mGluR5s) for behavioral and circuit abnormalities relevant to OCD.</p>
</sec>
<sec id="S2">
<title>METHODS</title>
<p id="P2"><italic>Sapap3</italic> knockout (KO) mice treated acutely with an mGluR5 antagonist were evaluated for OCD-relevant phenotypes of self-grooming, anxiety-like behaviors, and increased striatal activity. The role of mGluR5 in the striatal circuit abnormalities of <italic>Sapap3</italic> KO mice was further explored using two-photon calcium imaging to monitor striatal output from the direct and indirect pathways. A contribution of constitutive signaling to increased striatal mGluR5 activity in <italic>Sapap3</italic> KO mice was investigated using pharmacologic and biochemical approaches. Finally, sufficiency of mGluR5 to drive OCD-like behavior in wild-type mice was tested by potentiating mGluR5 with a positive allosteric modulator.</p>
</sec>
<sec id="S3">
<title>RESULTS</title>
<p id="P3">Excessive mGluR5 signaling underlies OCD-like behaviors and striatal circuit abnormalities in <italic>Sapap3</italic> KO mice. Accordingly, enhancing mGluR5 activity acutely recapitulates these behavioral phenotypes in wild-type mice. In <italic>Sapap3</italic> KO mice, elevated mGluR5 signaling is associated with constitutively active receptors and increased and imbalanced striatal output that is acutely corrected by antagonizing striatal mGluR5.</p>
</sec>
<sec id="S4">
<title>CONCLUSIONS</title>
<p id="P4">These findings demonstrate a causal role for increased mGluR5 signaling in driving striatal output abnormalities and behaviors with relevance to OCD and show the tractability of acute mGluR5 inhibition to remedy circuit and behavioral abnormalities.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Circuit</kwd>
<kwd>Constitutive activity</kwd>
<kwd>mGluR5</kwd>
<kwd>Obsessive-compulsive disorder</kwd>
<kwd>Positive allosteric modulator</kwd>
<kwd>Striatum</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>